About Aphranel： Where Science Meets the Poetics of Time

Aphranel is dedicated to advancing CaHA technology through continuous research and innovation.

Aphranel specializes in the development of advanced CaHA-based regenerative fillers, and within just one year since its launch, has rapidly emerged in the field of regenerative aesthetic medicine.

Who We Are

Headquartered in Shanghai, China, Aphranel is a flagship aesthetic brand under Moyom Biotech, founded in 2018. Since its global launch in May 2025, Aphranel has delivered over 150,000 syringes worldwide within its first year, gaining increasing trust among medical professionals. With a growing international presence and continuous product development, Aphranel is expanding across global markets, bridging scientific innovation with refined aesthetic outcomes.

Who We Are

A Journey Built on Time, Science, and Vision

Guangming Lin
Founder

True beauty is not about defying time, but embracing it as an ally.

At Aphranel, we do not fight against time, nor do we create anxiety around aging. We believe that everyone will age — and that beauty lies in accepting it, growing gracefully in your own way, and allowing beauty to evolve naturally.

Structure gives form, but time gives beauty its meaning — refined, evolving, and uniquely personal.

Innovation

Innovation at Aphranel is grounded in a long-term commitment to scientific research. We focus on the core parameters of CaHA biomaterials — including microsphere size distribution, porosity, and controlled degradation behavior — to ensure structural integrity and predictable clinical performance. Supported by systematic research, including in vitro testing, animal studies, and clinical validation, our approach is built on measurable evidence rather than short-term trends.

At the Forefront of Regenerative Innovation Since 2018

Aphranel was created with a clear intention —to redefine aesthetic medicine through science, structure, and time. Founded under Moyom Biotech in 2018, the brand was shaped by its founder’s long-term vision: to move beyond short-term trends and return aesthetic medicine to its scientific and medical foundation.

2013

2018

2025

2026

2013

The journey began with early-stage research as part of China’s national science and technology initiatives. During this period, foundational work in CaHA biomaterials was established, laying the groundwork for future innovation in structure and regeneration

2018

Shanghai Moyom Biotech was established by founder Lin Guangming

Foundational research in CaHA biomaterials was initiated under national science programs,leading to the establishment of Shanghai Moyom Biotechnology in 2018. Early development milestones included GMP facility construction, production validation, and the accumulation of over 35 national and 6 international invention patents.

2025

A major regulatory milestone

2025.02 Aphranel achieved with NMPA Class III medical device approval in China, becoming the first domestically developed CaHA-based product to reach this standard. 2025.05 — Aphranel marked its official launch at a global launch event in Shanghai, marking the official launch of Aphranel.

2025

International Certifications

Aphranel has obtained EU MD, MDSAP, and BGMP certifications, marking a significant step toward global regulatory compliance.

2026

More than 150,000 syringes had been delivered

Aphranel entered a new phase of brand evolution. In January,aphranel unveiled its global philosophy, “the Poetics of Time,” at an international launch event in Paris, marking the introduction of its time-based aesthetic framework. By May, marking the first anniversary of its global launch,more than 150,000 syringes had been delivered worldwide, reflecting growing trust among medical professionals and an expanding presence across global markets.

Keep reading

Page

Founder's Story

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

Page

Founder's Story

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

Page

Founder's Story

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX